We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+24.92%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$121M
AUM Growth
+$12.8M
Cap. Flow
-$3.03M
Cap. Flow %
-2.51%
Top 10 Hldgs %
72.03%
Holding
125
New
60
Increased
12
Reduced
11
Closed
25

Top Buys

Rank Stock Value
1
WTW icon
Willis Towers Watson
WTW
+$3.94M
2
TECD
Tech Data Corp
TECD
+$3.53M
3
CZR
Caesars Entertainment Corporation
CZR
+$3.46M
4
TIF
Tiffany & Co.
TIF
+$3.28M
5
LOGM
LogMein, Inc.
LOGM
+$2.89M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$19.3M
2
CY
Cypress Semiconductor
CY
+$6.27M
3
S
Sprint Corporation
S
+$5.7M
4
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$3.04M
5
MLNX
Mellanox Technologies, Ltd.
MLNX
+$2.79M

Sector Composition

Rank Sector Weight
1 Technology 43.2%
2 Healthcare 20.87%
3 Financials 13.46%
4 Consumer Discretionary 9.87%
5 Communication Services 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALA icon
51
KALA BIO
KALA
$14.5M
$420K 0.35%
+16
New +$453K
ZYME icon
52
Zymeworks
ZYME
$1.73B
$418K 0.35%
+11,593
New +$427K
BMRN icon
53
BioMarin Pharmaceuticals
BMRN
$13.5B
$417K 0.35%
+3,384
New +$336K
PTCT icon
54
PTC Therapeutics
PTCT
$6.15B
$416K 0.34%
+8,198
New +$403K
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$29.3B
$415K 0.34%
+2,805
New +$378K
AVDL
56
DELISTED
Avadel Pharmaceuticals
AVDL
$415K 0.34%
+51,408
New +$453K
RYTM icon
57
Rhythm Pharmaceuticals
RYTM
$7.95B
$415K 0.34%
+18,609
New +$363K
SRPT icon
58
Sarepta Therapeutics
SRPT
$1.89B
$412K 0.34%
+2,570
New +$350K
ZGNX
59
DELISTED
Zogenix, Inc.
ZGNX
$411K 0.34%
+15,217
New +$420K
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$408K 0.34%
+3,577
New +$347K
MYOK
61
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$408K 0.34%
+4,224
New +$352K
ALLK
62
DELISTED
Allakos
ALLK
$405K 0.34%
+5,635
New +$378K
FOLD
63
DELISTED
Amicus Therapeutics
FOLD
$405K 0.34%
+26,863
New +$327K
GBT
64
DELISTED
Global Blood Therapeutics, Inc.
GBT
$395K 0.33%
+6,261
New +$429K
MBT
65
DELISTED
Mobile TeleSystems Public Joint Stock Company American Depositary Shares (Each representing 2 Shares
MBT
$393K 0.33%
42,800
+18,400
+75% +$161K
MNTA
66
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$375K 0.31%
+11,266
New +$359K
BCEL
67
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$326K 0.27%
+15,330
New +$271K
CHKP icon
68
Check Point Software Technologies
CHKP
$13.1B
$301K 0.25%
+2,800
New +$297K
SCCO icon
69
Southern Copper
SCCO
$163B
$262K 0.22%
+7,205
New +$225K
XENE icon
70
Xenon Pharmaceuticals
XENE
$6.2B
$254K 0.21%
+20,239
New +$258K
SI
71
DELISTED
Silvergate Capital Corporation
SI
$190K 0.16%
13,579
-191,421
-93% -$2.58M
AKBA icon
72
Akebia Therapeutics
AKBA
$241M
$160K 0.13%
11,800
– –
TIMB icon
73
TIM SA
TIMB
$8.61B
$146K 0.12%
11,300
-900
-7% -$11.2K
QNST icon
74
QuinStreet
QNST
$1.2B
$130K 0.11%
+12,400
New +$120K
TPCO
75
DELISTED
Tribune Publishing Company Common Stock
TPCO
$112K 0.09%
+11,200
New +$100K
1 2
3
4 5

Similar funds

SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
PI
Pennant Investors Summit, New Jersey $361M AUM 134.26% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $361M AUM 38.29% 1-Year Est. Return

HighVista Strategies's Q2 2020 Portfolio in Review

As of Q2 2020, HighVista Strategies held 125 positions worth $121M, up 12% from $108M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

HighVista Strategies's Q2 2020 filing shows 60 new, 12 increased, 11 reduced and 25 closed positions. Its largest new stake was Caesars Entertainment Corporation: 342,418 shares worth $4.15M. The largest sale was Allergan plc, an estimated $19.3M.

By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 40% a quarter earlier, followed by Healthcare and Financials.

  • HighVista Strategies's largest Q2 2020 buy was Caesars Entertainment Corporation: 342,418 shares worth $4.15M.
  • HighVista Strategies added most to Willis Towers Watson in Q2 2020, an estimated $3.94M increase.
  • HighVista Strategies's biggest Q2 2020 reduction was Silvergate Capital Corporation, cutting an estimated $2.58M.
  • HighVista Strategies fully exited Allergan plc in Q2 2020, selling an estimated $19.3M.
  • HighVista Strategies's ten largest holdings make up 72% of its $121M portfolio in Q2 2020.
  • HighVista Strategies opened 60 new positions and closed 25 in Q2 2020.
  • HighVista Strategies's portfolio value rose 12% quarter-over-quarter to $121M.

Based on HighVista Strategies's 13F filing for Q2 2020, filed 14 Aug 2020.